导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.63% | 2507/4773 |
| 近一周 | -4.86% | 5291/5467 |
| 近一月 | -5.01% | 2090/5421 |
| 近一季 | -7.33% | 2304/5238 |
| 近半年 | -10.56% | 3735/4931 |
| 近一年 | 20.42% | 416/4400 |
| 近两年 | 75.67% | 901/2954 |
| 近三年 | 61.51% | 448/2253 |
| 成立以来 | 88.98% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
5.93% 317/4961 |
-5.75% 3615/5312 |
- - |
- - |
| 2025 | 57.83% 268/4813 |
1.45% 1618/3635 |
3.62% 975/4076 |
31.55% 1113/4524 |
14.13% 95/4813 |
| 2024 | 9.64% 1453/3463 |
13.88% 13/2808 |
-0.37% 754/3014 |
6.54% 2842/3129 |
-9.29% 2915/3463 |
| 2023 | -0.42% 452/2656 |
7.38% 582/2280 |
-4.62% 1224/2385 |
0.72% 348/2515 |
-3.48% 700/2655 |
| 2022 | -8.49% 155/2207 |
-0.87% 133/1919 |
6.33% 723/2016 |
-9.07% 242/2113 |
-4.53% 1892/2208 |
| 2021 | 36.50% 47/1822 |
4.74% 138/1255 |
10.94% 417/1330 |
25.51% 23/1466 |
-6.41% 1537/1822 |
| 2020 | 17.13% 768/1250 |
-15.59% 982/1028 |
3.66% 934/1067 |
7.41% 784/1164 |
24.63% 33/1184 |
| 2019 | 14.89% 695/1092 |
18.09% 645/754 |
-3.45% 397/804 |
-6.07% 803/850 |
7.28% 456/918 |
| 2018 | -31.80% 508/834 |
- - |
- - |
- - |
-16.20% 629/691 |
| 2017 | 20.91% 174/714 |
- - |
- - |
- - |
- - |
| 2016 | -2.43% 129/605 |
- - |
- - |
- - |
- - |
| 2015 | -7.88% 284/575 |
- - |
- - |
- - |
- - |
| 2014 | 30.09% 165/237 |
- - |
- - |
- - |
- - |
| 2013 | -37.70% 184/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 民生中证内地资源主题指数A VS. 长安沪深300非周期A(740101) |